Shire M&A machine stumbles on $30 bln Baxalta bid

August 4, 2015

The onetime Irish target for AbbVie is planning a mega-deal of its own. Unlike the previous combination, Shire’s Baxalta purchase has industrial logic as well as tax benefits. Shareholders, though, might have preferred being bought out to assuming all the risks of a takeover.

Teva exits Mylan mess with $40.5 bln Allergan deal

July 27, 2015

The Israeli pharma firm has been locked in a bitter battle to take over the Dutch drugmaker. Now it has agreed to buy the generic business from Allergan. The swap makes sense. Friendly is far easier than hostile, and the Allergan businesses are just as attractive as Mylan.

Breakdown: Watchdogs chew on health insurer deals

July 24, 2015

Anthem and Cigna are the latest big U.S. providers to serve up a blockbuster merger. But they and their peers need to satisfy a slew of regulators before chowing down. Here’s a look at the agencies and the transactions officials may be asked to swallow in a concentrated industry.

Latest pharma roll-up leaves lots of room to grow

July 7, 2015

Horizon’s $1.75 bln unsolicited offer for U.S. rival Depomed continues the sector’s M&A rave fueled by tax savings and cost cuts. The Irish bidder is a recent entrant on the scene, so its low debt load and small size means it can easily expand. That portends more deals ahead.

Healthcare M&A pumped after Obamacare booster shot

July 2, 2015

The U.S. top court decision upholding medical-coverage subsidies signals the official start of a race to consolidate. Centene and Health Net’s $6.3 bln deal gives the insurers an early lead. Big rivals like Cigna may catch up as the industry accepts that reform is here to stay.

Mega-rejections signal M&A’s Taylor Swift moment

June 22, 2015

U.S. health insurer Cigna brushed off a $54 bln takeover bid from Anthem while pipeline operator Williams spurned Energy Transfer’s $53 bln approach. Meantime, the 25-year-old pop idol forced Apple to pay up for music. In a hot market like this, love won’t be unrequited forever.

CVS-Omnicare portends lower doses of pharmacy M&A

May 21, 2015

The drugstore giant’s $10 bln purchase of the pharma services firm gives it entrance to nursing homes and expands specialty medicine distribution. But the increasingly concentrated industry is already raising antitrust concerns. The era of frantic mergers may be nearing an end.

TPG’s $8 bln drug sale far from generic

May 18, 2015

With the sale of Par Pharmaceutical, a maker of off-brand medicines, the buyout firm will generate an eight-fold return on its investment in three years. Though it’s a rare development, the eagerness of buyers like Endo International means more sellers are bound to benefit.

Danaher breakup eases sting of pricey Pall deal

May 13, 2015

The $60 bln dentures-to-lasers concern is not cutting enough costs to justify its $13.8 bln pounce for the filter maker. But boss Tom Joyce’s surprise decision to voluntarily split Danaher in two dangles the prospect of better value for shareholders. The trick is to deliver.

Pure play gets new spin in filter maker M&A

May 13, 2015

Suitors may be willing to splash out $13 bln for Pall, the largest publicly traded air and water purification company. That’s punchy and cost cuts might not cover the premium. But Pall’s scarcity value, profitability and burgeoning biotech customer base make it a tempting target.